Retatrutide (research code LY3437943) is an investigational synthetic peptide that has attracted attention in metabolic research because it engages three hormone receptors at once. This guide summarises the published, peer-reviewed evidence on retatrutide in a neutral, educational way for those following the scientific literature. It is written as laboratory and research information only. Retatrutide is not an approved medicine and has not been authorised by the MHRA, EMA, or FDA for human use; nothing here is medical advice, a dosing recommendation, or a claim of therapeutic benefit.
What is retatrutide?
Retatrutide is a single-molecule peptide developed by Eli Lilly that acts as an agonist at three receptors involved in energy and glucose metabolism: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. Because it targets all three, it is often described in the literature as a “GGG” or “triple-G” agonist. This sets it apart from single-receptor (GLP-1) and dual-receptor (GLP-1/GIP) compounds studied previously. It remains an investigational research compound, not a licensed product.
How does retatrutide work?
In preclinical and clinical research, the three receptor pathways are reported to contribute in complementary ways. GLP-1 receptor activity is associated with increased satiety and slowed gastric emptying; GIP receptor activity is associated with insulin secretion and effects on fat metabolism; and glucagon receptor activity is linked to increased energy expenditure and fat breakdown. The scientific interest in retatrutide lies in combining these mechanisms in one molecule, which researchers hypothesise may broaden its metabolic effects compared with agonists that act on only one or two of these receptors.
How is it characterised in studies?
In the published trials, retatrutide was administered as a once-weekly subcutaneous injection and has a reported half-life of roughly six days, which supports once-weekly dosing intervals in a controlled study setting. These pharmacokinetic details describe how the compound behaved within registered clinical research and are reported here for educational completeness, not as any instruction for use.
What does the research show?
The principal published evidence is a Phase 2 randomised, double-blind, placebo-controlled trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity and evaluated several once-weekly subcutaneous doses against placebo over 48 weeks. Its reported findings included:
- A mean reduction in body weight of approximately 24.2% from baseline at 48 weeks in the highest-dose group, versus roughly 2.1% with placebo.
- A dose-dependent response, with smaller but still measurable reductions at lower doses.
- Accompanying changes in metabolic markers such as fasting glucose and lipid measures reported by the investigators.
These are the results of one Phase 2 study and describe outcomes observed under controlled trial conditions; they are not a promise of any result and should be read alongside the trial’s own limitations.
What about safety in the trial?
The most commonly reported adverse events in the trial were gastrointestinal — nausea, vomiting, and diarrhoea — described as predominantly mild to moderate and generally dose-related, consistent with the broader incretin drug class. The study authors used gradual dose escalation in the protocol. Longer-term safety has not been established, and Phase 3 trials are designed to investigate it further. This summary is descriptive and does not constitute a safety assurance.
How does retatrutide compare with other agonists?
The main scientific distinction between retatrutide and earlier compounds is the number of receptors it targets. The table below summarises how three frequently compared research compounds differ by reported receptor activity. It is provided for educational comparison of the published literature only.
| Compound | Reported receptor targets | Class described in literature |
|---|---|---|
| Semaglutide | GLP-1 | Single-receptor agonist |
| Tirzepatide | GLP-1, GIP | Dual-receptor agonist |
| Retatrutide | GLP-1, GIP, glucagon | Triple-receptor (“GGG”) agonist |
Head-to-head Phase 3 comparisons are needed before any firm conclusions about relative efficacy can be drawn. Cross-trial comparisons of percentages from separate studies are not reliable evidence of superiority, so the table reflects mechanism, not a performance ranking.
Is retatrutide approved or legal in the UK?
As of 2026, retatrutide is an investigational compound. It has not been approved or granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA), or the US Food and Drug Administration (FDA). It is not a licensed medicine and is not approved for human consumption. Material supplied for research is intended for laboratory and educational research use only and must be handled in accordance with applicable local laws and institutional requirements. Its regulatory status may change as clinical development progresses.
What is the current state of ongoing research?
Following the Phase 2 results, a programme of larger Phase 3 trials has been undertaken to evaluate retatrutide’s longer-term effects across broader study populations. These studies are intended to inform any future regulatory review. Until that process concludes, conclusions about long-term safety, durability of effect, and comparative standing remain provisional. Researchers monitoring the field typically follow primary sources such as registered trial records and peer-reviewed journal publications rather than secondary summaries.
Where does retatrutide fit alongside other research peptides?
Within metabolic and body-composition research, retatrutide is sometimes studied in the context of other research peptides. For laboratory researchers building a reference library, related research-grade compounds such as ipamorelin research formulations and IGF-1 LR3 peptides are also studied in metabolic and tissue research contexts. Researchers interested specifically in this compound can review high-purity retatrutide for research. These references are provided for laboratory research purposes only and imply no medical, therapeutic, or human-use application.
Research references
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. DOI: 10.1056/NEJMoa2301972 (PMID: 37366315).
- Patti ME. Triple G Agonists — A Home Run for Obesity? N Engl J Med. 2023;389(6):562–563. DOI: 10.1056/NEJMe2307282 (editorial).
- ClinicalTrials.gov. A Study of LY3437943 (Retatrutide) in Participants Who Have Obesity or Are Overweight. Identifier NCT04881760, sponsor Eli Lilly and Company.
Research-use disclaimer: This article is provided for laboratory and educational research information only. Retatrutide is an investigational compound that is not an approved medicine and has not been evaluated by the MHRA, EMA, or FDA for human use. Nothing here is medical advice, a dosing guideline, or a claim of therapeutic benefit, and these materials are not intended for human consumption. Consult a qualified healthcare professional for medical questions.